VolitionRx feline cancer blood test study shows 86% sensitivity at 97% specificity

VolitionRX Ltd

VNRX

0.00

VolitionRx submitted for peer review a clinical manuscript on May 6, 2026 covering its Nu.Q Vet Feline prototype blood test for detecting lymphoma in cats; results have not yet been published.
Study reported strong diagnostic performance in distinguishing cats with lymphoma from healthy controls, supporting use as a screening aid.
Peer-reviewed publication is expected to trigger a USD 5 million contractual milestone payment.
Company positioned feline launch as incremental growth lever alongside existing Nu.Q Vet Canine rollout, citing potential to expand companion-animal addressable market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060817PR_NEWS_USPR_____LN52597) on May 06, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.